MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 CAR T-cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma.
Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.
